- Home
- ARCL vs CHRS Comparison
ARCL vs CHRS Comparison
Compare ARCL & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$1.02
Company Overview
Basic Information| Metric | ARCL | CHRS |
|---|---|---|
| Founded | 2025 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 178.4M | 159.1M |
| IPO Year | 2025 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ARCL | CHRS |
|---|---|---|
| Price | $10.01 | $1.02 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $7.75 |
| AVG Volume (30 Days) | 22.4K | ★ 1.3M |
| Earning Date | N/A | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 472.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $44.19 |
| Revenue Next Year | N/A | $65.06 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.88 | $0.94 |
| 52 Week High | $10.03 | $2.62 |
Technical Indicators
Market Signals| Indicator | ARCL | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 57.51 | 40.32 |
| Support Level | $9.97 | $0.97 |
| Resistance Level | $10.02 | $1.53 |
| Average True Range (ATR) | 0.01 | 0.07 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 72.73 | 36.84 |
Price Performance
Historical Comparison ARCL
CHRS
About ARCL ARC Group Acquisition I Corp Class A Ordinary Shares
ARC Group Acquisition I Corp is a blank check company.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.